Patients with lung adenocarcinoma and colon adenocarcinoma that expressed low levels of BTNL2 had significantly improved survival compared to those expressing high levels of BTNL2 (Fig. 6a, b). The gene discussed is BTNL2; the disease is colon adenocarcinoma.